eMedicine Specialties > Pediatrics: Genetics and Metabolic Disease > Genetics

Nail-Patella Syndrome

Author: Julie Hoover-Fong, MD, PhD, FACMG, Assistant Professor, Director, Greenberg Center for Skeletal Dysplasias, McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University
Coauthor(s): Iain McIntosh, PhD, Professor of Medical Genetics, Chair, Department of Molecular and Cell Biology, Director, Stephen Gaffin Research Laboratory, American University of the Carribean; Elizabeth Sweeney, MBChB, MD, Consultant Clinical Geneticist, Royal Liverpool Children's Hospital, UK
Contributor Information and Disclosures

Updated: Oct 20, 2009

Introduction

Background

Nail-patella syndrome (NPS; OMIM 161200) is an autosomal dominant condition characterized by the classical clinical tetrad of nail dysplasia, patellar aplasia-hypoplasia, elbow arthrodysplasia, and iliac horns. The nails may be absent, hypoplastic, or dystrophic with ridges, pits, and/or triangular lunulae.

Nail of a patient the nail-patella syndrome.

Nail of a patient the nail-patella syndrome.

Nail of a patient the nail-patella syndrome.

Nail of a patient the nail-patella syndrome.


Typically, nail anomalies are symmetric; the thumbs are most severely affected, and severity decreases progressing toward the fifth digit. The patella may be absent, small, or irregularly shaped. Dislocation in a superior and lateral direction is common if patellae are present. Elbow anomalies may include decreased extension, pronation, supination, and/or pterygia. Patellae and elbow anomalies may be asymmetric. The iliac horns are bony prominences that project posterolaterally from the iliac bones. Although rarely palpable, they are radiographically visible in most patients with nail-patella syndrome.

Proteinuria with or without hematuria occurs in 30-50% of affected individuals, but progresses to end-stage renal disease in approximately 5% of patients.1 Ocular hypertension and open-angle glaucoma is more common in younger patients than in the general population. The third documented chromosomal linkage identified in humans was between the nail-patella syndrome locus and the ABO blood group on chromosome 9. LMX1B, located at 9q34.1, is an LIM-homeodomain transcription factor required for the normal development of dorsal limb structures, the glomerular basement membrane, the anterior segment of the eye, and dopaminergic and serotonergic neurons. Heterozygous loss-of-function mutations in LMX1B cause nail-patella syndrome.2,3

Pathophysiology

Although the joint anomalies in nail-patella syndrome may limit range of motion (ROM), the associated glaucoma and nephropathy may be the most serious complication. Asymptomatic proteinuria may persist for years; however, end-stage renal failure occurs in less than 5%. 

Mutations in the homeodomain of LMX1B versus LIM-A or LIM-B may be associated with proteinuria. However, further investigation of a larger population of patients with nail-patella syndrome (ideally sporadic) is needed to determine if this genotype-phenotype correlation is valid outside large pedigrees of nail-patella syndrome, which may be simultaneously segregating nephropathy-related genes.

Frequency

United States

Nail-patella syndrome has been recognized for more than 100 years. It has an estimated prevalence of 1 per 50,000 live births.

International

Nail-patella syndrome has been described in multiple populations.

Mortality/Morbidity

The severity of clinical features and manifestations cannot be predicted. Orthopedic problems may be treated with analgesics, physical therapy, bracing, and/or surgery. With concurrent renal disease, nonsteroidal anti-inflammatory drugs (NSAIDs) must be used cautiously to avoid worsening renal function. If orthopedic surgery is planned, MRI prior to surgery is recommended because joint structures (ie, ligament, tendon and muscle insertions, vessel locations) are typically distorted in patients with nail-patella syndrome.

Renal disease that manifests as proteinuria with or without hematuria occurs in 30-50% of patients, but progression to end-stage renal disease occurs in less than 5%. Hypertension and renal disease are treated as in the general population, with recognition that ACE inhibitors have been shown to slow progression of proteinuria in nail-patella syndrome. Patients who have undergone renal transplantation usually have good results. Glaucoma should also be treated as in the general population, but with increased surveillance in all patients with nail-patella syndrome (eg, annual ophthalmologic examination with glaucoma screening).

Race

No race predilection has been reported.

Sex

Males and females are equally affected.

Age

Prenatal diagnosis based on ultrasonography detection of iliac horns is reported; talipes may also be detected on antenatal ultrasonography. Nail anomalies and contractures of the knees or elbows may be noted at birth. Abnormal patellae are often noted in early childhood. Renal disease may occur at any age. When present, the onset of glaucoma or ocular hypertension is usually in adulthood but at an earlier age than in the general population. Other disease manifestations span all ages.

Clinical

History

  • Family history: Collect a full 3 generation pedigree to detect family history of autosomal dominant nail-patella syndrome (NPS). Currently, 88% of affected individuals have a positive family history of nail-patella syndrome. Nail-patella syndrome is fully penetrant, but significant interfamilial and intrafamilial variability is noted.
  • Nail/digit anomalies: Nail anomalies are present at birth.
  • Knees: Recurrent patellar dislocations, deformity of knee joint, and knee pain are noted.
  • Elbows: Elbow pain, decreased flexion, pronation, and supination are reported.
  • Back pain: This is common in nail-patella syndrome; underlying spinal problems such as spondylolisthesis may be observed.
  • Renal disease: Proteinuria, hypertension, and/or decreased renal function may be observed in patients with nail-patella syndrome. End-stage renal disease is relatively rare and is reported in approximately 5% of patients.
  • Preeclampsia: This condition is more common in patients with nail-patella syndrome than in the general population.
  • Ophthalmology: Ocular hypertension or open-angle glaucoma may be observed.
  • Neurology: Attention deficit disorder with and without hyperactivity (ADHD) may be more common in adults with nail-patella syndrome and does not exhibit the same increased male prevalence as in the general population. Major depressive symptoms may also be part of the syndrome. A significant proportion of patients exhibit decreased sensitivity to pain and temperature in the extremities. Signs and symptoms of chronic fatigue may be present due to maldevelopment of the serotonergic system.
  • GI problems: Constipation and irritable bowel syndrome are more common in patients with nail-patella syndrome than in the general population.

Physical

  • Nail/digit anomalies: Nails may be absent, hypoplasia, or dystrophic; triangular lunulae may be the sole nail anomaly. Typically, the thumb is most severely affected, with possible decreasing severity progressing to the fifth digit. Decreased creases over the distal interphalangeal (DIP) joints are noted.
  • Patellar anomalies: Patellae may be absent or hypoplastic. Dislocation in the superior and lateral direction is common. Pain is also common and osteoarthritis may be present.
  • Iliac horns: These bony prominences are typically asymptomatic and may be palpable on the posterolateral iliac bones. If not palpable, they are often detected using radiography. They are present in about 70% of patients and are pathognomonic of nail-patella syndrome.
  • Elbow anomalies: Decreased flexion, supination, and pronation are noted. The radius may be hypoplastic and posteriorly placed. Skin webbing (pterygia) may be present.
  • Renal disease: Proteinuria with or without hematuria may be present in 30-50% of patients. This progresses to end-stage renal disease in approximately 5%. No evidence suggests that renal transplantation has different outcome in patients with nail-patella syndrome than in the general population.
  • Open-angle glaucoma: Optic nerve and visual field damage can be prevented with early detection of elevated intraocular pressure and appropriate treatment.
  • Lester sign: A hyperpigmented, irregular ring in the iris may be noted.

Causes

  • The LMX1B gene is a transcription factor involved in the dorsoventral patterning of vertebrate limbs (including patterning of the nails, digits, elbows and patellae), the differentiation and function of kidney podocytes, development of the anterior eye structures, and the CNS. 
  • The loss of function of one allele of LMX1B is the only known cause of nail-patella syndrome.

More on Nail-Patella Syndrome

Overview: Nail-Patella Syndrome
Differential Diagnoses & Workup: Nail-Patella Syndrome
Treatment & Medication: Nail-Patella Syndrome
Follow-up: Nail-Patella Syndrome
Multimedia: Nail-Patella Syndrome
References

References

  1. Sweeney E, Fryer A, Mountford R, Green A, McIntosh I. Nail patella syndrome: a review of the phenotype aided by developmental biology. J Med Genet. Mar 2003;40(3):153-62. [Medline].

  2. Bongers EM, van Kampen A, van Bokhoven H, Knoers NV. Human syndromes with congenital patellar anomalies and the underlying gene defects. Clin Genet. Oct 2005;68(4):302-19. [Medline].

  3. McIntosh I, Dunston JA, Liu L, Hoover-Fong JE, Sweeney E. Nail patella syndrome revisited: 50 years after linkage. Ann Hum Genet. Jul 2005;69(Pt 4):349-63. [Medline].

  4. [Guideline] Papnicolaou N, Francis IR, Casalino DD, et al. ACR Appropriateness Criteria renal failure. [online publication]. Reston (VA): American College of Radiology (ACR); 2008. [Full Text].

  5. Azouz EM, Kozlowski K. Small patella syndrome: a bone dysplasia to recognize and differentiate from the nail-patella syndrome. Pediatr Radiol. May 1997;27(5):432-5. [Medline].

  6. Bennett WM, Musgrave JE, Campbell RA, et al. The nephropathy of the nail-patella syndrome. Clinicopathologic analysis of 11 kindred. Am J Med. Mar 1973;54(3):304-19. [Medline].

  7. Bongers EM, Huysmans FT, Levtchenko E, et al. Genotype-phenotype studies in nail-patella syndrome show that LMX1B mutation location is involved in the risk of developing nephropathy. Eur J Hum Genet. Aug 2005;13(8):935-46. [Medline].

  8. Browning MC, Weidner N, Lorentz WB Jr. Renal histopathology of the nail-patella syndrome in a two-year-old boy. Clin Nephrol. Apr 1988;29(4):210-3. [Medline].

  9. Chen H, Lun Y, Ovchinnikov D, et al. Limb and kidney defects in Lmx1b mutant mice suggest an involvement of LMX1B in human nail patella syndrome. Nat Genet. May 1998;19(1):51-5. [Medline].

  10. Cormier-Daire V, Chauvet ML, Lyonnet S, et al. Genitopatellar syndrome: a new condition comprising absent patellae, scrotal hypoplasia, renal anomalies, facial dysmorphism, and mental retardation. J Med Genet. Jul 2000;37(7):520-4. [Medline].

  11. Cottereill CP, Jacobs P. Hereditary Arthro-osteo-onchyodysplasia associated with iliac horns. Br J Clin Pract. 1961;15(11):933-941.

  12. Curtis JJ, Bhathena D, Leach RP, Galla JH, Lucas BA, Luke RG. Goodpasture's syndrome in a patient with the Nail-Patella syndrome. Am J Med. Sep 1976;61(3):401-6. [Medline].

  13. Dai JX, Johnson RL, Ding YQ. Manifold functions of the Nail-Patella Syndrome gene Lmx1b in vertebrate development. Dev Growth Differ. Apr 2009;51(3):241-50. [Medline].

  14. Darlington D, Hawkins, CF. Nail patella syndrome with iliachorns and hereditary nephropathy: necropsy report and anatomical dissection. J Bone Joint Surg [Am]. Jan 1967;49B:164-74. [Medline].

  15. Dreyer SD, Zhou G, Baldini A, et al. Mutations in LMX1B cause abnormal skeletal patterning and renal dysplasia in nail patella syndrome. Nat Genet. May 1998;19(1):47-50. [Medline].

  16. Dunston JA, Hamlington JD, Zaveri J, et al. The human LMX1B gene: transcription unit, promoter, and pathogenic mutations. Genomics. Sep 2004;84(3):565-76. [Medline].

  17. Dunston JA, Reimschisel T, Ding YQ, et al. A neurological phenotype in nail patella syndrome (NPS) patients illuminated by studies of murine Lmx1b expression. Eur J Hum Genet. Mar 2005;13(3):330-5. [Medline].

  18. Eisenberg KS, Potter DE, Bovill EG Jr. Osteo-onychodystrophy with nephropathy and renal osteodystrophy. A case report. J Bone Joint Surg [Am]. Sep 1972;54(6):1301-5. [Medline].

  19. Feingold M, Itzchak Y, Goodman RM. Ultrasound prenatal diagnosis of the Nail-Patella syndrome. Prenat Diagn. Aug 1998;18(8):854-6. [Medline].

  20. Fong EE. 'Iliac horns' (symmetrical bilateral central posterior iliac processes):a case report. Radiology. 1946;47:517-518.

  21. Galloway G, Vivian A. An ophthalmic screening protocol for nail-patella syndrome. J Pediatr Ophthalmol Strabismus. Jan-Feb 2003;40(1):51-3. [Medline].

  22. Krawchuk D, Kania A. Identification of genes controlled by LMX1B in the developing mouse limb bud. Dev Dyn. Apr 2008;237(4):1183-92. [Medline].

  23. Leahy MS. The hereditary nephropathy of osteo-onychodysplasia. Nail-patella syndrome. Am J Dis Child. Sep 1966;112(3):237-41. [Medline].

  24. Lemley KV. Kidney disease in nail-patella syndrome. Pediatr Nephrol. Jun 6 2008;[Medline].

  25. Looij BJ Jr, te Slaa RL, Hogewind BL, van de Kamp JJ. Genetic counselling in hereditary osteo-onychodysplasia (HOOD, nail- patella syndrome) with nephropathy. J Med Genet. Oct 1988;25(10):682-6. [Medline].

  26. McIntosh I, Clough MV, Gak E. Prenatal diagnosis of nail-patella syndrome [letter]. Prenat Diagn. Mar 1999;19(3):287-8. [Medline].

  27. Mimiwati Z, Mackey DA, Craig JE, Mackinnon JR, Rait JL, Liebelt JE. Nail-patella syndrome and its association with glaucoma: a review of eight families. Br J Ophthalmol. Dec 2006;90(12):1505-9. [Medline].

  28. Morita T, Laughlin LO, Kawano K, et al. Nail-Patella syndrome. Light and electron microscopic studies of the kidney. Arch Intern Med. Feb 1973;131(2):271-7. [Medline].

  29. Sabnis SG, Antonovych TT, Argy WP, et al. Nail-patella syndrome. Clinical Nephrology. Sep 1980;14(3):148-53. [Medline].

  30. Schulz-Butulis BA, Welch MD, Norton SA. Nail-patella syndrome. J Am Acad Dermatol. Dec 2003;49(6):1086-7. [Medline].

Further Reading

Keywords

nail-patella syndrome, NPS, Fong disease, NPS 1, onycho-osteodysplasia, hereditary onycho-osteodysplasia disease, HOOD, Turner-Kieser syndrome, arthro-onychodysplasia, nephrotic syndrome, end-stage renal disease, ESRD, end-stage renal failure, ESRF, , proteinuria, spondylolisthesis, attention deficit disorder, ADD, attention deficit hyperactivity disorder, ADHD, constipation, irritable bowel syndrome, IBS, osteoarthritis, treatment, diagnosis

Contributor Information and Disclosures

Author

Julie Hoover-Fong, MD, PhD, FACMG, Assistant Professor, Director, Greenberg Center for Skeletal Dysplasias, McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University
Julie Hoover-Fong, MD, PhD, FACMG is a member of the following medical societies: American College of Medical Genetics, American Society of Human Genetics, and International Skeletal Dysplasia Society
Disclosure: Nothing to disclose.

Coauthor(s)

Iain McIntosh, PhD, Professor of Medical Genetics, Chair, Department of Molecular and Cell Biology, Director, Stephen Gaffin Research Laboratory, American University of the Carribean
Iain McIntosh, PhD is a member of the following medical societies: American Society of Human Genetics
Disclosure: Nothing to disclose.

Elizabeth Sweeney, MBChB, MD, Consultant Clinical Geneticist, Royal Liverpool Children's Hospital, UK
Elizabeth Sweeney, MBChB, MD is a member of the following medical societies: British Society of Human Genetics
Disclosure: Nothing to disclose.

Medical Editor

Christian J Renner, MD, Consulting Staff, Department of Pediatrics, University Hospital for Children and Adolescents, Erlangen, Germany
Disclosure: Nothing to disclose.

Pharmacy Editor

Mary L Windle, PharmD, Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy, Pharmacy Editor, eMedicine
Disclosure: Pfizer Inc Stock Investment from financial planner; Avanir Pharma Stock Investment from financial planner ; WebMD Salary and stock Employment and investment from financial planner

Managing Editor

Leonard G Feld, MD, PhD, MMM, FAAP, Sara H Bissell and Howard C Bissell Endowed Chair in Pediatrics, Chief Medical Officer, Levine Children's Hospital, Carolinas Medical Center
Leonard G Feld, MD, PhD, MMM, FAAP is a member of the following medical societies: American Academy of Pediatrics, American College of Physician Executives, American Society of Nephrology, American Society of Pediatric Nephrology, International Society of Nephrology, and Juvenile Diabetes Foundation International
Disclosure: Nothing to disclose.

CME Editor

Daniel Rauch, MD, FAAP, Director, Pediatric Hospitalist Program, Associate Professor, Department of Pediatrics, New York University School of Medicine
Daniel Rauch, MD, FAAP is a member of the following medical societies: Ambulatory Pediatric Association, American Academy of Pediatrics, and Society of Hospital Medicine
Disclosure: Baxter Honoraria Consulting

Chief Editor

Bruce Buehler, MD, Professor, Department of Pediatrics, Pathology and Microbiology, Executive Director, Hattie B Munroe Center for Human Genetics, University of Nebraska Medical Center
Bruce Buehler, MD is a member of the following medical societies: American Academy for Cerebral Palsy and Developmental Medicine, American Academy of Pediatrics, American Association on Mental Retardation, American College of Medical Genetics, American College of Physician Executives, American Medical Association, and Nebraska Medical Association
Disclosure: Nothing to disclose.

RELATED EMEDICINE ARTICLES
RELATED MEDSCAPE ARTICLES
Articles
 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.